Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research

4037 - Cemiplimab, a human PD-1 monoclonal antibody, in patients (pts) with recurrent or metastatic cervical cancer: Interim data from Phase 1 cohorts


20 Oct 2018


Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research


Clinical Research

Tumour Site

Cervical Cancer


Danny Rischin


Annals of Oncology (2018) 29 (suppl_8): viii332-viii358. 10.1093/annonc/mdy285


D. Rischin1, M. Gil-Martin2, A. González-Martín3, I. Brana4, J.Y. Hou5, D. Cho6, G.S. Falchook7, S. Formenti8, S. Jabbour9, K. Moore10, A. Naing11, K.P. Papadopoulos12, J. Baranda13, A. Weise14, M.G. Fury15, M. Feng16, J. Li17, I. Lowy15, M. Mathias15

Author affiliations

  • 1 Department Of Medical Oncology, Peter MacCallum Cancer Centre and the University of Melbourne, Victoria 300 - Melbourne/AU
  • 2 L’hospitalet De Llobregat, Institut Català d’Oncologia, 08908 - Barcelona/ES
  • 3 Clinica Universidad De Navarra, Formerly of MD Anderson International España, Madrid/ES
  • 4 Department Of Medical Oncology, Vall D’Hebron Institute of Oncology, Barcelona/ES
  • 5 Division Of Gynecologic Oncology, Columbia University Medical Center, New York/US
  • 6 Langone Medical Center, New York University, New York/US
  • 7 Drug Development, Sarah Cannon Research Institute at HealthONE, 80218 - Denver/US
  • 8 Department Of Radiation oncology, Weill Cornell Medicine, 10065 - New York/US
  • 9 Department Of Radiation oncology, Rutgers Cancer Institute of New Jersey, New Brunswick/US
  • 10 Stephenson Cancer Center At The University Of Oklahoma Health Sciences Center, Sarah Cannon Research Institute, Oklahoma City/US
  • 11 Department Of Investigational Cancer Therapeutics (phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, 77030-4095 - Houston/US
  • 12 Clinical research, START, 78229 - San Antonio/US
  • 13 University Of Kansas Cancer Center, Early Phase Program Clinical research Center, Fairway/US
  • 14 Department Of Medical Oncology, Karmanos Cancer Institute, Detroit/US
  • 15 Clinical Sciences, Regeneron Pharmaceuticals, Inc., Tarrytown/US
  • 16 Clinical Sciences, Oncology, Regeneron Pharmaceuticals, Inc., 07920 - Basking Ridge/US
  • 17 Biostatistics & Data Management, Regeneron Pharmaceuticals, Inc., 07920 - Basking Ridge/US


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 4037


For pts who progress after first–line platinum based therapy for recurrent/metastatic cervical cancer, there are no therapies available that have been demonstrated to improve survival or quality of life. Cemiplimab (REGN2810), a human monoclonal antibody to PD-1, exhibited encouraging efficacy and acceptable tolerability in a phase 1 dose escalation study. The present report focuses on interim data from the phase 1 cervical cancer expansion cohorts (ECs) of cemiplimab as a monotherapy (EC 23) or in combination with hypofractionated radiotherapy (hfRT) (EC 24) (NCT02383212).


Pts with recurrent or metastatic cervical cancer resistant to or intolerant of platinum and taxane doublet therapy received cemiplimab 3 mg/kg Q2W for up to 48 weeks, in ECs 23 and 24, and hfRT (9 Gy x 3 times/week given 1 week after first dose of cemiplimab) in EC 24. The co-primary objectives were to evaluate the safety, tolerability, and efficacy of cemiplimab monotherapy or in combination with hfRT. Tumour response assessments (in non-irradiated target lesions) were performed by RECIST 1.1 Q8W.


As of 1 Sept, 2017, these ECs were fully enrolled with 20 pts (EC 23, n = 10, EC 24, n = 10). Median (range) age was 55.0 (31–76) years (EC 23) and 51.5 (29–65) years (EC 24). ECOG performance status 1 vs. 0 was 60% vs. 40% and 80% vs. 20%, respectively, for EC 23 and EC 24. Investigator-assessed overall response rate (ORR; complete response [CR] + partial response [PR]) was 10.0% (0 CR and 1 PR) in each of EC 23 and EC 24. At the time of data cut-off, both responses were ongoing with durations of 3.7+ months. The most common treatment-emergent adverse events (TEAEs) of any grade were diarrhoea (40.0%), fatigue, hypokalaemia and pain in extremity (each 30.0%) in EC 23, and diarrhoea and urinary tract infection (each 30.0%) in EC 24. There was no grade ≥3 TEAE reported in > 1 patient in either cohort.


Cemiplimab as monotherapy and in combination with hfRT demonstrated antitumour activity with an acceptable safety profile in pts with metastatic or recurrent cervical cancer. Cemiplimab monotherapy vs. chemotherapy in ≥ 2nd line cervical cancer is currently being evaluated in a global randomised phase 3 study (NCT03257267).

Clinical trial identification


Legal entity responsible for the study

Regeneron Pharmaceutical, Inc. and Sanofi.


Regeneron Pharmaceutical, Inc. and Sanofi.

Editorial Acknowledgement

Medical writing support under the direction of the authors was provided by Emmanuel Ogunnowo, PhD, of Prime (Knutsford, UK) and funded by Regeneron Pharmaceuticals, Inc. and Sanofi.


D. Rischin: Research funding: Genentech/Roche, Merck, Amgen, Regeneron, Bristol-Myers Squibb. A. González-Martín: Consulting, Advisory, Speakers’ bureau and Travel accommodation expenses: AstraZeneca, Tesaro, Roche, Pharmamar. J.Y. Hou: Consultant and receives fees: Foundation Medicine, Massive Bio, Inc. D. Cho: Consulting fees: Pfizer, BMS, Exelixis, Genentech, Prometheus. G.S. Falchook: Funding: Regeneron Pharmaceuticals for trial for submitted work. S. Jabbour: Research funding grants: Merck, Nestle outside of the submitted work. K. Moore: Institutional consultancy (honorarium and ad board) fees: Tesaro, Genentech Roche, Clovis, AstraZeneca (for agents not involved in the SOLO-1 study), Immunogen, VBL Therapeutics, Janssen. M.G. Fury: Employee of and shareholder: Regeneron Pharmaceuticals, Inc.; Patents, royalties, other intellectual property: Regeneron Pharmaceuticals, Inc. M. Feng: Employee and shareholder: Regeneron Pharmaceuticals, Inc., Bayer. J. Li: Employee and shareholder: Regeneron Pharmaceuticals, Inc., Novartis. I. Lowy: Employee of, shareholder of, and fees for travel and accommodation expenses as well as leadership: Regeneron Pharmaceuticals, Inc. M. Mathias: Employee and shareholder: Regeneron Pharmaceuticals, Inc. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.